Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diabetes Management During Breastfeeding in Women with Type 1 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

    Research output: Contribution to journalReviewResearchpeer-review

  3. Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls

    Research output: Contribution to journalReviewResearchpeer-review

  5. Metabolomic Biomarkers in the Progression to Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pregnancy loss is associated with type 2 diabetes: a nationwide case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.
Original languageEnglish
JournalCurrent Diabetes Reports
Volume10
Issue number2
Pages (from-to)124-32
Number of pages9
ISSN1534-4827
DOIs
Publication statusPublished - 1 Apr 2010

ID: 32275276